Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alternaria allergy immunotherapy - Probelte Pharma

Next Previous
Drug Profile

Alternaria allergy immunotherapy - Probelte Pharma

Alternative Names: Beltavac Polimerizado; BeltavacPolimerizado; SCIT - Probelte Pharma; Subcutaneous allergen-specific immunotherapy - Probelte Pharma

Latest Information Update: 29 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Probelte Pharma
  • Class Allergens; Antiallergics; Fungal allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Allergic asthma; Allergic rhinoconjunctivitis

Most Recent Events

  • 08 Jul 2026 Probelte Pharma plans a phase III trial for Allergic rhinoconjunctivitis (In adolescents, In adults, In the elderly) in Spain (SC, Injection) (CTIS2026-526105-15-00)
  • 14 Sep 2025 Probelte Pharma plans phase II trial in Allergic rhinoconjunctivitis (In adults) in Spain and Poland(SC) (CTIS2023-510033-28-00) (EudraCT-2023-510033-28-00)
  • 09 Jun 2025 Probelte Pharma plans a phase II trial in Allergic rhinoconjunctivitis (Treatment experienced) in Spain, Poland (CTIS2025-520581-22-00)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top